... targets for several cardiovascular disorders including heart failure (HF) such as beta-adrenergic receptor (βAR) blockers and angiotensin II receptor (AT1R) antagonists. The activity of GPCRs are finely regulated by GPCR kinases (GRKs), which phosphorylate agonist-occupied receptors and start the process...

... heart failure hypertension phosphate small molecules Plasma phosphate (P i ) is tightly controlled in the range from 0.9 to 1.45 mmol L −1 in healthy adults [ 1 ], and requires a concerted interplay between intestinal uptake, storage/release from bone, and renal excretion. The kidney plays...

... failure and a major cause of morbidity and mortality worldwide with no effective treatment. Single-cell RNA-sequencing (scRNA-seq) offers a promising new platform to identify new cellular and molecular protagonists that may drive cardiac fibrosis and development of heart failure. This review...

... 2020 19 9 2020 22 9 2020 © 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2020 corin heart failure hypertension protease domains Atrial natriuretic peptide (ANP)-mediated vasodilation and natriuresis are important mechanisms...

...Lisha Ma Chronic heart failure is a common consequence of various heart diseases. Mechanical force is known to play a key role in heart failure development through regulating cardiomyocyte hypertrophy. In order to understand the complex disease mechanism, this article discussed a multi-disciplinary...

... enhanced in polyP-depleted cells demonstrating that polyP protects cardiac myocytes against enhanced ROS formation. Furthermore, polyP concentration was dynamically changed during activation of the mitochondrial respiratory chain and stress conditions such as ischaemia/reperfusion (I/R) and heart failure...

... that are several orders of magnitude lower than those required for underivatized 8-CPT [ 46 ]. cAMP cardiac disease exchange protein directly activated by cAMP (Epac) G-protein-coupled receptor (GPCR) heart failure phosphodiesterase cAMP is an ubiquitous second messenger that plays a critical...

... 2012 cAMP exchange protein directly activated by cAMP (Epac) G-protein-coupled receptor guanine-nucleotide-exchange factor heart failure protein kinase A (PKA) cAMP is a universal second messenger which is produced from ATP by adenylate cyclase upon activation of G s PCRs (G s...

...Alessandra Stangherlin; Manuela Zaccolo cAMP and cGMP signalling pathways are common targets in the pharmacological treatment of heart failure, and often drugs that modulate the level of these second messengers are simultaneously administered to patients. cGMP can potentially affect cAMP levels...

... and affinity for Ca 2+ ions to the physiological demand of the heart. Dysregulation of the SERCA2a activity entails poor cardiomyocyte contractility, resulting in heart failure. Conversely, improving cardiac SERCA2a activity, e.g. by boosting its expression level or by increasing its affinity for Ca 2...

.... Mol. Cell. Biol. 1999 19 6286 6296 11 Dodge K.L. Khouangsathiene S. Kapiloff M.S. Mouton R. Hill E.V. Houslay M.D. Langeberg L.K. Scott J.D. EMBO J. 2001 20 1921 1930 cAMP compartmentalization heart failure phosphodiesterase 3B (PDE3B...

... is expressed dominantly in the heart. 17 6 2005 © 2005 The Biochemical Society 2005 adenylate cyclase aortic banding cardiac myocyte apoptosis genetic manipulation heart failure P-site inhibitor The autonomic nervous system is a major mechanism of regulating cardiac function...